Literature DB >> 1540788

Antinuclear and antineutrophil cytoplasmic antibodies (ANCA) in the sera of patients with Felty's syndrome.

A Juby1, C Johnston, P Davis, A S Russell.   

Abstract

The prevalence of antinuclear (ANA) and antineutrophil cytoplasmic antibodies (ANCA) has been studied in the sera of 62 patients with rheumatoid arthritis and 32 patients with Felty's syndrome. The presence of ANA was less in RA than Felty's syndrome (37% versus 69%). Specific autoantibody identification, where possible, was usually of SS-A or SS-B although two sera from patients with Felty's syndrome had low levels of DNA antibody. ANCA was detected in the sera of 33% of patients with Felty's syndrome and was absent in RA sera. The pattern of ANCA staining was either of a diffuse homogenous cytoplasmic or peripheral (pANCA) nature. Classical cytoplasmic granular staining (cANCA) was not identified.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1540788     DOI: 10.1093/rheumatology/31.3.185

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  13 in total

1.  Rational requesting or rationing testing?

Authors:  R J Lock
Journal:  J Clin Pathol       Date:  2004-02       Impact factor: 3.411

2.  Felty's syndrome treated with rhG-CSF associated with flare of arthritis and skin rash.

Authors:  M F McMullin; M B Finch
Journal:  Clin Rheumatol       Date:  1995-03       Impact factor: 2.980

Review 3.  The clinical utility of ANCA positivity.

Authors:  J D Edgar
Journal:  Ann Rheum Dis       Date:  1996-08       Impact factor: 19.103

4.  Antineutrophil cytoplasmic antibodies (ANCA) in rheumatoid arthritis: a prospective study.

Authors:  E Röther; T Schochat; H H Peter
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

5.  Autoantibodies and target antigens in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides.

Authors:  J A Savige; L Chang; D Wilson; R R Buchanan
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

Review 6.  ANCA in diseases other than systemic vasculitis.

Authors:  H H Peter; D Metzger; A Rump; E Röther
Journal:  Clin Exp Immunol       Date:  1993-09       Impact factor: 4.330

Review 7.  The clinical relevance of ANCA in vasculitis.

Authors:  W L Gross; S Hauschild; N Mistry
Journal:  Clin Exp Immunol       Date:  1993-09       Impact factor: 4.330

8.  Anti-neutrophil cytoplasm antibodies (ANCA) in rheumatoid arthritis: relationship to HLA-DR phenotypes, rheumatoid factor, anti-nuclear antibodies and disease severity.

Authors:  E Röther; D Metzger; B Lang; I Melchers; H H Peter
Journal:  Rheumatol Int       Date:  1994       Impact factor: 2.631

9.  An audit of ANCA in routine clinical practice.

Authors:  J D Edgar; S A McMillan; I N Bruce; S K Conlan
Journal:  Postgrad Med J       Date:  1995-10       Impact factor: 2.401

Review 10.  ANCA and associated diseases: immunodiagnostic and pathogenetic aspects.

Authors:  W L Gross; W H Schmitt; E Csernok
Journal:  Clin Exp Immunol       Date:  1993-01       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.